Perceptive Advisors - Q3 2023 holdings

$3 Billion is the total value of Perceptive Advisors's 97 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .

 Value Shares↓ Weighting
CERE  CEREVEL THERAPEUTICS HLDNG I$220,229,445
-31.3%
10,088,3850.0%7.35%
-20.9%
 LIANBIOsponsored ads$85,762,091
-34.6%
57,558,4510.0%2.86%
-24.7%
ALDX  ALDEYRA THERAPEUTICS INC$75,818,568
-20.4%
11,350,0850.0%2.53%
-8.2%
MGTX  MEIRAGTX HLDGS PLC$55,635,715
-26.9%
11,331,1030.0%1.86%
-15.8%
LYRA  LYRA THERAPEUTICS INC$49,882,067
-4.9%
12,757,5620.0%1.66%
+9.6%
BBIO  BRIDGEBIO PHARMA$46,119,363
+53.3%
1,748,9330.0%1.54%
+76.6%
IMTX  IMMATICS N.V$40,431,570
+0.3%
3,491,5000.0%1.35%
+15.7%
NAUT  NAUTILUS BIOTECHNOLOGY INC$28,791,237
-18.3%
9,111,1510.0%0.96%
-6.0%
 ACRIVON THERAPEUTICS INC$28,755,122
-26.2%
3,007,8580.0%0.96%
-15.0%
TARS  TARSUS PHARMACEUTICALS INC$23,037,312
-1.7%
1,296,4160.0%0.77%
+13.3%
VRCA  VERRICA PHARMACEUTICALS INC$19,576,448
-32.7%
5,038,9830.0%0.65%
-22.4%
 ASTRIA THERAPEUTICS INC$16,333,387
-10.4%
2,189,4620.0%0.54%
+3.2%
RLAY  RELAY THERAPEUTICS INC$16,341,445
-33.0%
1,943,0970.0%0.54%
-22.8%
CRY  ARTIVION INC$14,119,296
-11.8%
931,3520.0%0.47%
+1.7%
BMEA  BIOMEA FUSION$9,858,228
-37.3%
716,4410.0%0.33%
-27.7%
ATHA  ATHIRA PHARMA INC$9,690,501
-31.5%
4,797,2780.0%0.32%
-21.2%
 SOLID BIOSCIENCES INC$8,809,751
-51.9%
3,495,9330.0%0.29%
-44.5%
FUSN  FUSION PHARMACEUTICALS INC$7,153,627
-44.3%
2,751,3950.0%0.24%
-35.8%
 LANDOS BIOPHARMA INC$5,769,525
-7.8%
1,486,9910.0%0.19%
+6.1%
 TYRA BIOSCIENCES INC$4,957,200
-19.1%
360,0000.0%0.16%
-6.8%
 ENVVENO MEDICAL CORPORATION$4,212,905
+75.0%
781,6150.0%0.14%
+101.4%
XFOR  X4 PHARMACEUTICALS INC$3,864,545
-43.8%
3,545,4540.0%0.13%
-35.2%
 SOMALOGIC INC$3,585,000
+3.5%
1,500,0000.0%0.12%
+20.0%
ARQT  ARCUTIS BIOTHERAPEUTICS INCput$2,622,500
+85.0%
300,0000.0%0.09%
+112.2%
KRON  KRONOS BIO INC$2,278,568
-24.4%
1,752,7450.0%0.08%
-12.6%
 ACELYRIN INC$2,034,000
-51.3%
200,0000.0%0.07%
-43.8%
 VBI VACCINES INC CDA$925,507
-79.6%
1,381,3550.0%0.03%
-76.5%
OMIC  SINGULAR GENOMICS SYSTEMS IN$900,385
-54.1%
2,363,2140.0%0.03%
-47.4%
 MOTUS GI HLDGS INC$40,512
-32.8%
90,0270.0%0.00%
-50.0%
 EQRX INC*w exp 12/17/202$10,000
-76.5%
250,0000.0%0.00%
-100.0%
 SURROZEN INC*w exp 08/01/203$6,667
-33.3%
166,6660.0%0.00%
CMAXW  CAREMAX INC*w exp 06/08/202$11,250
-51.9%
60,0000.0%0.00%
-100.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings